Abstract Background There are concerns that glucagon-like peptide-1 receptor agonists (GLP1s) increase the risk of acute pancreatitis
Consumer brands growing from beach-town startups into national businesses
The Evernorth benefit program caps expenses at $200 monthly, potentially generating annual savings of $3,600 compared to standard retail pricing
It is the patient. Look at the scientific evidence, Rothberg says

individual results vary significantly Both medications require adherence to dosing schedule and lifestyle modifications Higher doses generally produce better results but may have more side effects Not everyone reaches maximum doses due to side effect tolerance Actual weight loss depends on starting weight, diet, exercise, and individual metabolism Time to See Results: Semaglutide: Weeks 1-4: Minimal weight loss (adjusting to medication) Weeks 4-12: Noticeable appetite reduction and initial weight loss (5-8 pounds) Weeks 12-24: Steady weight loss (1-2 pounds per week) Weeks 24-68: Continued weight loss at slower pace Tirzepatide: Weeks 1-4: Minimal weight loss (adjusting to medication) Weeks 4-12: Noticeable appetite reduction and initial weight loss (8-12 pounds) Weeks 12-24: Steady weight loss (1.5-2.5 pounds per week) Weeks 24-72: Continued weight loss, often at sustained pace Both medications show continued weight loss throughout the clinical trial periods, with weight loss plateauing around month 16-20 for most participants

PMID: 41815755 References are provided for research reference only